Mylona-Karayanni C, Hadziargurou D, Liapi-Adamidou G, Anagnostakis I, Sinaniotis C, Saxoni-Papageorgiou F
Second Department of Pediatrics, University of Athens, "P. & A. Kyriakou" Children's Hospital, Greece.
J Asthma. 1990;27(2):87-93. doi: 10.3109/02770909009073302.
Ketotifen was administered orally, for 3 months, to 40 children aged 3-14 years with chronic extrinsic asthma of moderate severity in a double-blind placebo-controlled study. A significant clinical improvement with concomitant reduction of antiasthmatic drugs was found in the group receiving the active drug compared with the placebo group (p less than 0.05). The continued administration of ketotifen in an open study to a group of 21 children comprised of patients belonging to both groups (active-placebo) for a period of 15-18 months resulted in disappearance of symptoms in 10 children (47.6%) and moderate improvement in 7 (33.3%).
在一项双盲安慰剂对照研究中，对40名3至14岁患有中度严重程度慢性外源性哮喘的儿童口服酮替芬，持续3个月。与安慰剂组相比，接受活性药物的组出现了显著的临床改善，同时抗哮喘药物的用量减少（p<0.05）。在一项开放性研究中，对由两组（活性药物组-安慰剂组）的患者组成的21名儿童持续给予酮替芬，为期15至18个月，结果10名儿童（47.6%）症状消失，7名儿童（33.3%）有中度改善。
